Clinical Trials Logo

Granulomatous Mastitis clinical trials

View clinical trials related to Granulomatous Mastitis.

Filter by:

NCT ID: NCT05852171 Recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

Baricitinib in Idiopathic Granulomatous Mastitis

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.

NCT ID: NCT05409586 Completed - Clinical trials for Idiopathic Granulomatous Mastitis

Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis

Start date: April 20, 2022
Phase:
Study type: Observational

Albumin-to-globulin ratio (AGR) is an inflammation-based index that has been shown to have a role in many cancers and inflammatory diseases. Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with a high recurrence rate. As a relatively new biomarker for inflammatory diseases, AGR's role in IGM recurrence has never been investigated in the literature. This study primarily investigates the possible risk factors for IGM recurrence and whether AGR can be used as a predictive factor.

NCT ID: NCT05395949 Enrolling by invitation - Clinical trials for Psychiatric Disorder

A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders

GLMwPD
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Granulomatous lobular mastitis (GLM) is a relatively rare chronic inflammatory disease of the breast in clinical practice. A small number of patients develop hyperprolactinemia during psychiatric drug treatment, and most of these patients are nulliparous. At present, there is no unified treatment mode at home and abroad, and surgery is generally the main treatment. GLM is a sterile inflammation, and glucocorticoids and methotrexate can effectively relieve clinical symptoms and even reach the standard of cure. In order to reduce the recurrence rate and protect the breast appearance as much as possible, we propose a conservative therapy. The purpose of this study was to compare this conservative therapy of granulomatous lobular mastitis with existing surgical treatment, and to compare the overall benefits of the two for patients with GLM. We aim to protect the breast appearance on the premise of low recurrence, improve the quality of life of GLM patients with psychiatric disorders .

NCT ID: NCT05361629 Recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

Idiopathic Granulomatous Mastitis Combination Therapy

IGM-COMBO
Start date: April 16, 2022
Phase: N/A
Study type: Interventional

After breast cancer, diopathic Granulomatous Mastitis (IGM) is among the breast diseases that bother patients and clinicians the most. Countries with a coast to the Mediterranean, especially our country, are the most common geography of this disease. For this reason, a significant part of the important scientific publications about IGM in the last 3-4 decades are from the countries of this geography and mainly from our country. The paradigm of whether IGM should be treated medically or surgically is still a matter of debate. Today, effective treatment results can be achieved with medical treatments, and local drug applications are finding an increasing application area in order to reduce the systemic drug level due to the side effects often seen in this process. As in the centers dealing with breast diseases intensively in our country, patients are treated in our center both by systemic and local means. Within the body of the Turkish Breast Diseases Federation, after the plans made with the employees of the leading breast centers of the International Breast Health Working Group International planned to start a recording study to observe the activity between, local treatment in the lesion without surgical treatment with systemic treatment in IGM treatment and local treatment together with surgical treatment.

NCT ID: NCT04596046 Completed - Clinical trials for Granulomatous Mastitis

Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis?

IGM
Start date: November 19, 2019
Phase: N/A
Study type: Interventional

Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory breast disease that mimics malignancy owing to its features of appearance.In our research, we intended to compare the efficiency of local (intralesional) steroid administration with systemic (peroral) steroid. A total of 36 patients who had been histopathologically diagnosed with IGM and whose other factors had been microbiologically excluded were included in the study. The patients were randomized into two sub-groups that would be treated with systemic and local steroids. Of the patients, 19 were administered with 0.5-1 mg/kg/day peroral systemic steroid, and 17 were administered with 40-200 mg/ml intralesional local steroid regarding the severity of the lesion. All patients were evaluated through physical examination one week after the completion of the treatment. Subsequently, the follow-up of the patients was performed thorough physical examination and ultrasonography and/or magnetic resonance imaging at the 1st, 3rd, and 6th months.

NCT ID: NCT04543149 Completed - Clinical trials for Granulomatous Mastitis

Immune Cells in Patients With Granulomatous Mastitis

Start date: August 1, 2020
Phase:
Study type: Observational

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. Etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. Our aim in this study is to examine the role of immunophenotyping in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

NCT ID: NCT04540237 Completed - Clinical trials for Granulomatous Mastitis

Serum Cytokine Values in Patients With Granulomatous Mastitis

Start date: September 1, 2020
Phase:
Study type: Observational

Granulomatous mastitis is a rare, chronic, benign inflammatory disease of the breast that plays a role in many varying etiologies, including infectious and non-infectious causes. Etiological reasons were examined in various studies, but neither etiology nor definite criteria for diagnosis were found. Our aim in this study is to examine the role of cytokines in differentiating the etiology of granulomatous mastitis and using it as a prognostic marker.

NCT ID: NCT04424615 Not yet recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

Idiopathic Granulomatous Mastitis

IGM
Start date: October 2020
Phase:
Study type: Observational

Assessment of incidence, diagnosis and treatment of idiopathic granulomatous mastitis in Assiut university hospital

NCT ID: NCT04096300 Active, not recruiting - Clinical trials for Idiopathic Granulomatous Mastitis

An Integrative Approach for Idiopathic Granulomatous Mastitis.

IIGM
Start date: June 1, 2019
Phase:
Study type: Observational

Collaboration is established between Turkish Holistic & Integrative Medicine Association and Traditional & Complementary Medicine Society of Istanbul Medipol University. Study is carried out on idiopathic granulomatous mastitis patients who are followed in the Breast Clinic at Istanbul Medipol University Hospital for between September 2015 and September 2019. Hirudotherapy and medical cupping therapy were applied as traditional and complementary medicine integratively. Following initial radiological imaging, microbiological- and histological testing, side effects and relapses are analyzed. Follow-up examination is also carried out at the end of the treatment, which consisted of clinical breast exam and radiological imaging.

NCT ID: NCT03766997 Recruiting - Clinical trials for Granulomatous Mastitis

Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)

LSTIGM
Start date: February 19, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the clinical response rate of local steroids in the treatment of idiopathic granulomatous mastitis in female adults. Half of the participants will receive local injection combined with topical steroids and the other half will receive topical steroids mono-therapy.